Skip to content

In the BioHarmony Drug Report Database


Addyi (flibanserin) is a small molecule pharmaceutical. Flibanserin was first approved as Addyi on 2015-08-18. The pharmaceutical is active against 5-hydroxytryptamine receptor 1A and 5-hydroxytryptamine receptor 2A. Addyi's patents are valid until 2023-05-09 (FDA).
Trade Name Addyi
Common Name Flibanserin
Drug Class Serotonin 5-HT2 receptor antagonists
Get full access now